Welcome to our dedicated page for Progyny SEC filings (Ticker: PGNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
When you research Progyny, the first numbers you chase are live-birth success rates, employer contract renewals, and network clinic costs. Those details hide inside dense SEC documents, not glossy press releases. This page gathers every Progyny SEC filing explained simply, so you no longer sift through hundreds of pages to verify margin trends or Smart Cycle utilization rates.
Use our AI-powered summaries to jump directly to what matters: the Progyny annual report 10-K simplified spotlights outcome statistics and revenue per member, while the latest Progyny quarterly earnings report 10-Q filing breaks down reimbursement shifts and new client wins. Sudden contract announcements? The Progyny 8-K material events explained section flags them within minutes of hitting EDGAR. If you’re tracking leadership incentives, our system streams Progyny Form 4 insider transactions real-time, alerting you to every Progyny executive stock transactions Form 4.
Here’s how professionals use the page:
- Compare quarter-over-quarter embryo transfer success rates with one-click Progyny earnings report filing analysis.
- Monitor governance changes through the Progyny proxy statement executive compensation link to gauge retention costs.
- Stay ahead of market moves with instant notifications on Progyny insider trading Form 4 transactions.
Progyny, Inc. announced that the employment of its President, Michael Sturmer, will end effective December 31, 2025, with severance provided under his existing 2021 employment agreement. The company is not appointing a new President, noting that it has strengthened its executive team with recent hires in commercial, technology, operations and product leadership roles.
To support continuity on key projects and strategic initiatives, Sturmer will remain as a non-employee consultant through December 31, 2026, under a new consulting agreement. He will receive an annual advisory fee of $250,000, and if he continues to serve through June 30, 2026, his outstanding and vested stock options will have their exercisability extended proportionally to the period of consulting services. The full consulting agreement will be filed as an exhibit to Progyny’s Annual Report on Form 10-K for the year ending December 31, 2025.
Progyny, Inc. reported an insider stock transaction by its chief financial officer, Mark S. Livingston. On December 11, 2025, he sold 459 shares of Progyny common stock at $25.5 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan that was entered into on August 15, 2025. Following this transaction, he directly owns 46,983 shares of Progyny common stock.
Progyny, Inc.'s president reported a routine equity compensation-related share withholding. On 12/04/2025, 7,977 shares of common stock were withheld at $24.55 per share to pay withholding taxes triggered by the vesting of restricted stock units granted to the officer. After this transaction, the president directly beneficially owned 288,233 Progyny shares.
Progyny, Inc. (PGNY) reported an insider stock sale by its Chief Financial Officer. On 11/17/2025, the CFO sold 21,303 shares of Progyny common stock at a price of $25.50 per share, as shown in Table I of the filing. After this transaction, the CFO beneficially owns 48,358 shares of common stock in a direct capacity.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan that was entered into on August 15, 2025. These plans allow insiders to systematically sell shares according to preset instructions, helping separate personal liquidity decisions from day-to-day company developments.
Progyny, Inc. (PGNY) director reported an option exercise and a share transfer. On 11/14/2025, the reporting person exercised a stock option for 36,224 shares of common stock at $1.45 per share, paying the exercise price in cash and holding all shares received, with no shares sold in connection with the exercise.
On 11/18/2025, the reporting person transferred 50,265 shares held directly to The Norman C. and Melinda B. Payson Revocable Trust for no consideration, reported as a gift. Following these transactions, the person held common stock directly and also indirectly through the revocable trust and through EVO Eagle, LLC, over which the reporting person shares voting and dispositive power.
Progyny, Inc. (PGNY) disclosed that its Chief Executive Officer and director purchased 79,500 shares of common stock on 11/13/2025. The shares were bought at a weighted average price of $24.288 per share, in multiple trades at prices ranging from $23.73 to $24.52. Following this transaction, the reporting person beneficially owns 680,251 shares directly and an additional share indirectly through PECO ANEVSKI 2020 SD LLC. The filing notes that the purchase was made to offset a tax withholding obligation arising from the net settlement of performance stock units reported the same day.
Progyny, Inc. (PGNY) Form 4: The Executive Chairman and director reported the vesting and settlement of performance stock units. On 11/10/2025, 41,500 PSUs granted on January 1, 2022 were settled into common stock after the Compensation Committee certified performance on 10/31/2025.
To cover withholding taxes upon vesting, 21,286 shares were withheld at $22.37. Following these transactions, the reporting person directly beneficially owns 240,633 shares. These entries reflect equity award settlement and related tax withholding, not an open‑market purchase or sale.
Progyny, Inc. (PGNY)
On November 10, 2025, the reporting person acquired 125,000 shares of common stock at $0 upon settlement of PSUs that vested on October 31, 2025, after certification of performance. On the same date, 63,813 shares were withheld to cover taxes at a price of $22.37 per share. Following these transactions, the filer beneficially owned 600,751 shares directly, plus 1 share held indirectly.
Progyny, Inc. (PGNY) reported stronger Q3 2025 results. Revenue rose to $313.3M from $286.6M, with gross profit of $72.8M. Operating income increased to $21.5M and net income reached $13.9M, or $0.15 diluted EPS. For the first nine months, revenue was $970.3M and net income was $46.0M, reflecting solid year-to-date performance.
Liquidity remained healthy: cash and cash equivalents were $134.0M and marketable securities were $211.2M at quarter end. Operating cash flow for the nine months was $156.0M. The company entered a $200M revolving credit facility maturing in 2030, with no borrowings outstanding, and later authorized a new $200M share repurchase program in November 2025. Total assets were $795.2M and stockholders’ equity was $560.0M. As of October 31, 2025, 86,211,654 common shares were outstanding.
Client base and utilization supported growth: Q3 fertility benefits revenue was $201.9M and pharmacy benefits revenue was $111.4M. The company closed the Benefit Bump acquisition for $10.5M to extend family support offerings.
Progyny (PGNY) furnished an update on its latest results. The company announced financial results for the fiscal quarter ended September 30, 2025 and made these materials available to investors.
A press release and a supplemental earnings presentation were furnished as Exhibit 99.1 and Exhibit 99.2, respectively, and are also accessible via the investor relations site. The information furnished under Items 2.02 and 7.01, including these exhibits, is provided as furnished, not filed.
FAQ
What is the current stock price of Progyny (PGNY)?
What is the market cap of Progyny (PGNY)?
